Biocon Biologics Limited (BBL) has announced that the Government of Malaysia has approved a six-month extension to its current insulin supply contract. The extension will be effective from April 29, 2025, to October 28, 2025.
This extension pertains to the existing agreement between Biocon Sdn. Bhd., a subsidiary of Biocon Biologics in Malaysia, and Duopharma Marketing Sdn. Bhd. (DMktg), the company’s commercial partner in the region. The original three-year contract, awarded in 2022, was scheduled to end in April 2025.
Biocon Biologics has been supplying insulin to Malaysia’s Ministry of Health (MoH) for nearly a decade. The insulin products are manufactured at Biocon’s facility located in Johor, Malaysia. These recombinant human insulin products are then distributed in the country through DMktg.
The extension will be formalized through a supplementary agreement between the Ministry of Health, Duopharma Marketing, and Biocon Biologics.
The company states that it remains focused on providing access to affordable insulin therapies for patients in Malaysia and globally.
